Nanovibronix (NASDAQ:FEED) Posts Quarterly Earnings Results

Nanovibronix (NASDAQ:FEEDGet Free Report) released its earnings results on Monday. The company reported ($1.98) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $0.24 million during the quarter. Nanovibronix had a negative net margin of 923.20% and a negative return on equity of 54.25%.

Nanovibronix Price Performance

Shares of Nanovibronix stock opened at $0.46 on Tuesday. The stock has a market cap of $2.83 million, a PE ratio of -0.05 and a beta of 1.39. The firm has a fifty day moving average price of $0.51 and a 200 day moving average price of $1.34. Nanovibronix has a 1 year low of $0.29 and a 1 year high of $17.40.

Insider Buying and Selling

In other Nanovibronix news, insider Christian Michael Glibert sold 210,000 shares of the company’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $0.69, for a total value of $144,900.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 12.20% of the company’s stock.

Analysts Set New Price Targets

FEED has been the topic of several research analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nanovibronix in a research note on Tuesday, July 21st. Wall Street Zen upgraded Nanovibronix from a “strong sell” rating to a “sell” rating in a research note on Sunday, July 12th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

Get Our Latest Stock Report on FEED

Nanovibronix Company Profile

(Get Free Report)

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.

Featured Stories

Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.